In one study the authors failed to find meaningful hematological and clinical correlates, nor a clear prognostic value [78], while in another study including a larger cohort of MPN patients, NFE2 mutations adversely affected prognosis, increasing the risk of BP progression independently of age and other co-occurring mutations [79]. The gene discussed is NFE2; the disease is myeloproliferative disorder.